Cristina Campos Gonçalves

Dr. Cristina Campos Gonçalves

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
MSMargarida Simão
Margarida Simão
CGCristina Campos Gonçalves
Cristina Campos Gonçalves
The Hepatitis C Virus (HCV) is a significant public health challenge in European countries. Historically, healthcare-related procedures were the primary source of HCV infection in Europe. However, with the implementation of blood safety programs, injection drug use has become the main transmission route. The infection’s distribution and genotype prevalence vary widely across the continent. Even with the availability of highly effective direct-acting antiviral (DAA) therapies, HCV infection is far from being controlled. A significant proportion of patients remain undiagnosed, contributing to the ongoing transmission of the virus. Additionally, several barriers hinder the widespread use of DAAs, including high treatment costs, stigma, poor linkage to care, and considerable geographical variations in prevalence and transmission routes. The World Health Organization has set ambitious targets to reduce liver-related deaths, decrease new viral hepatitis infections, and ensure that 90% of infected individuals are diagnosed by 2030. However, most European countries face challenges, highlighting the need for screening programs, funding mechanisms, and public health strategies to effectively control HCV infection in Europe.

5 November 2024 in GE - Portuguese Journal of Gastroenterology
Verified
Journal Article
Open access
FCFilipe Calinas
Filipe Calinas
HCHélder Cardoso
Hélder Cardoso
SCSofia Carvalhana
Sofia Carvalhana
JFJosé Ferreira
José Ferreira
CGCristina Campos Gonçalves
Cristina Campos Gonçalves
RSRui M. Santos
Rui M. Santos
Wilson disease (WD) is a genetic disorder of copper metabolism caused by mutations in the ATP7B gene resulting in toxic copper accumulation in several organs. WD can manifest as liver disease, a progressive neurological disorder, a psychiatric illness, or a combination of these. Other clinical manifestations can also occur. Diagnosis is challenging and typically requires a range of biochemical tests, imaging, genetic testing for ATP7B, and/or liver biopsy. WD is treatable with chelating agents, such as d-penicillamine and trientine, and/or zinc salts alongside with dietary copper restriction. Liver transplantation may be indicated in WD patients with severe hepatic disease, and cautiously considered in patients with neurological WD. Treatment success highly depends on patient adherence and treatment persistence. Therefore, effective interventions for improving patient adherence and close monitoring are key for preventing WD progression. In Portugal, there are no reference centers for WD, and patients are dispersed across numerous medical specialists. This review aimed to summarize the most recent and relevant information for the diagnosis, treatment, and monitoring of WD in Portugal, as well as possible interventions for stimulating adherence to treatment.

28 April 2021 in GE - Portuguese Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
LRLuís Rodrigues
Luís Rodrigues
SASofia Almeida
Sofia Almeida
CSCatarina Salgado
Catarina Salgado
CGCristina Campos Gonçalves
Cristina Campos Gonçalves
Introduction: Sickle cell intrahepatic cholestasis (SCIC) is one of the rarest and the most severe acute hepatic manifestations of sickle cell disease (SCD) and it can rapidly progress to acute liver failure. It is associated with a high mortality rate, demanding prompt recognition and management. Case Presentation: We report a case of a 7-year-old boy with a history of homozygous HbS SCD who presented to the emergency department with fever, increasing abdominal pain, and jaundice. His course was complicated by acute liver injury (AST 9,472 IU/L, ALT 2,683 IU/L, total bilirubin 15.4 mg/dL; conjugated bilirubin 8.69 mg/dL, hypoalbuminemia 2.6 g/dL, and persistent hypoglycemia), with acute liver failure (coagulopathy not corrected by vitamin K administration with INR 3.26, decreased factors V 10% and VII 28%, and West Haven grade I hepatic encephalopathy associated with mild hyperammonemia of 71 µmol/L). After excluding other causes of acute liver failure, the patient was diagnosed as having SCIC and was successfully treated with manual exchange transfusion. Conclusion: This case reinforces that exchange transfusion is an effective treatment for SCIC and that it should be introduced promptly to prevent fulminant and potentially fatal liver failure.

28 April 2025 in PAJAR - Pan-American Journal of Aging Research
Verified
Journal Article
Open access
PDF file
OCOvidio Costa
Ovidio Costa
SMSara Moura-Ferreira
Sara Moura-Ferreira
RSRui Cunha e Sousa
Rui Cunha e Sousa
MCManuel Campos
Manuel Campos
CGCristina Campos Gonçalves
Cristina Campos Gonçalves
A cardiomiopatia (CM) amiloide é causada pela deposição de proteínas insolúveis amiloides. Pode ter causa primária, ser herdada ou secundária. A CM amiloide por transtirretina do tipo selvagem (ATTR wt) e a amiloidose por cadeias leves (AL) são os tipos mais comuns. Manifesta-se por dispneia, fadiga e edemas resistentes à terapêutica. O diagnóstico assenta na existência de cenários típicos e de red flags, tais como identificação de hipertrofia ventricular esquerda não justificada associada à padrão de baixa voltagem, estenose valvular aórtica (ou TAVI), síndrome do túnel do carpo bilateral, entre outros. A imunofixação sérica e urinária e o doseamento de cadeias livres séricas confirma ou exclui, quase sempre, a hipótese de diagnóstico de CM AL. A biópsia dos depósitos amiloides é essencial nesses casos. A cintilografia óssea é muito sensível para a CM ATTR e permite o diagnóstico clínico não invasivo. Doentes mais velhos com uma ecocardiografia/ressonância magnética cardíaca sugestivas de CM amiloide e cintigrafia com captação miocárdica de ⁹⁹ᵐTc são fortemente suspeitos de CM ATTRwt. O teste genético deve realizar-se para diferenciar a ATTRwt da variantes mutantes (ATTRv). O tratamento específico de cada amiloidose inclui o manejo das síndromes clínicas (insuficiência cardíaca, síndrome nefrótica, neuropatia…) e deve realizar-se em centro especializado. Os custos do tratamento farmacológico da cardiomiopatia amiloidótica por transtirretina poderão vir a ser desafiadores no nosso país em consequência do esperado aumento do uso no tratamento da CM amiloide e custo-efetividade/impacto orçamental associado à respetiva utilização.

30 September 2025 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
CNCatarina Nunes
Catarina Nunes
LRLuísa Ribeiro
Luísa Ribeiro
MTMaria Torre
Maria Torre
CGCristina Campos Gonçalves
Cristina Campos Gonçalves
This case report illustrates a rare case of progressive familial intrahepatic cholestasis type 3. Pruritus was the predominant symptom that led to the diagnosis of this condition in an otherwise healthy adolescent. The onset of symptoms can happen at any age, and the diagnosis may be delayed due to a lack of severe symptoms. Genetic testing confirms the diagnosis. Therapy with ursodeoxycholic acid is recommended, and other anti-pruritic medications can be adjuvant. Disease progression should be monitored.

31 August 2026 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
PDF file
BKBenno Kohlmaier
Benno Kohlmaier
GIGiuseppe Indolfi
Giuseppe Indolfi
UBUlrich Baumann
Ulrich Baumann
CGCristina Campos Gonçalves
Cristina Campos Gonçalves
EGEmmanuel GONZALES
Emmanuel GONZALES
EFEmer Fitzpatrick
Emer Fitzpatrick
Hepatitis B virus (HBV) infection remains a global health challenge, with more than 250 million people chronically infected worldwide and >2000 daily deaths from HBV‐related disease. Early‐life acquisition is the primary driver of chronic infection; up to 90% of infants infected perinatally progress to chronic HBV infection compared with markedly lower rates in older children and adults. Universal infant immunization, including the birth‐dose, has been central to global elimination, resulting in a substantial reduction in chronic HBV infection, cirrhosis, and hepatocellular carcinoma. Recent statements from the Centers for Disease Control and Prevention question the evidence‐base for early‐life vaccination and recommend deferring HBV immunization until later in childhood. These claims reflect misconceptions about HBV epidemiology and reference a perceived association between infant vaccination and autism. This communication summarizes evidence demonstrating the risks of early‐life HBV transmission leading to chronic infection. We argue that delaying or foregoing immunization would leave infants at unnecessary risk. We reference two decades of research in which large‐scale studies have not identified an association between vaccination, including HBV vaccination, and autism.